Abstract
Objectives: To compare a contrast agent with high iodine concentration with an iso-osmolar contrast agent for coronary dual-source computed tomography angiography (DS-CTA), and to assess whether the contrast agent characteristics may affect the diagnostic quality of coronary DS-CTA. Materials and Methods: Patients were randomized to receive either 80 mL of iodixanol-320 (Visipaque, GE Healthcare, Chalfont St. Giles, United Kingdom) or iomeprol-400 (Iomeron, Bracco Imaging SpA, Milan, Italy) at 5 mL/s. Mean, minimum, maximum heart rate, and its variation (max-min) were assessed during calcium scoring scan and coronary DS-CTA. Three off-site readers independently evaluated the image sets in terms of technical adequacy, reasons for inadequacy, vessel visualization, diagnostic confidence (based on a 5-point scale), and arterial contrast opacification in Hounsfield units (HUs). Results: Ninety-six patients were included in the final evaluation. No significant differences were observed for pre-and postdose heart rate values for iomeron-400 compared with iodixanol-320, and changes in heart rate variation were also not significantly different (-2.3 ± 11.7 vs.-2.5 ± 7.3 bpm, P > 0.1). Contrast measurements in all analyzed vessels were significantly higher for iomeprol-400 (mean, 391.5-441.4 HU) compared with iodixanol-320 (mean, 332.3-365.5 HU, all P ≤ 0.0038). There was no significant difference in qualitative visualization of coronary arteries (mean scores, 4.3-4.5 for iomeprol, 4.1-4.3 for iodixanol, P = 0.15-0.28), or in diagnostic confidence scores. HU were inversely correlated with the number of insufficiently opacified segments (all readers P ≤ 0.0006). Conclusions: The high-iodine concentration contrast medium iomeprol-400 demonstrated significant benefit for coronary arterial enhancement compared with the iso-osmolar contrast medium iodixanol-320 when administered at identical flow rates and volumes for coronary DS-CTA. In addition, higher enhancement levels were found to be associated with lower numbers of inadequately visualized segments. Finally, observed mean heart rate changes after intravenous contrast injection were generally small during the examination and comparable for both agents.
| Original language | English |
|---|---|
| Pages (from-to) | 457-464 |
| Number of pages | 8 |
| Journal | Investigative Radiology |
| Volume | 46 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 2011 |
Fingerprint
Keywords
- Coronary arteries
- Dual-source computed tomography
- Heart rate
- Hounsfield units (HU)
- Iodixanol
- Iomeprol
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Cite this
Multicenter comparison of high concentration contrast agent iomeprol-400 with iso-osmolar iodixanol-320 : Contrast enhancement and heart rate variation in coronary dual-source computed tomographic angiography. / Becker, Cristoph R.; Vanzulli, Angelo; Fink, Christian; De Faveri, Daniele; Fedeli, Stefano; Dore, Roberto; Biondetti, Pietro; Kuettner, Alex; Krix, Martin; Ascenti, Giorgio.
In: Investigative Radiology, Vol. 46, No. 7, 07.2011, p. 457-464.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Multicenter comparison of high concentration contrast agent iomeprol-400 with iso-osmolar iodixanol-320
T2 - Contrast enhancement and heart rate variation in coronary dual-source computed tomographic angiography
AU - Becker, Cristoph R.
AU - Vanzulli, Angelo
AU - Fink, Christian
AU - De Faveri, Daniele
AU - Fedeli, Stefano
AU - Dore, Roberto
AU - Biondetti, Pietro
AU - Kuettner, Alex
AU - Krix, Martin
AU - Ascenti, Giorgio
PY - 2011/7
Y1 - 2011/7
N2 - Objectives: To compare a contrast agent with high iodine concentration with an iso-osmolar contrast agent for coronary dual-source computed tomography angiography (DS-CTA), and to assess whether the contrast agent characteristics may affect the diagnostic quality of coronary DS-CTA. Materials and Methods: Patients were randomized to receive either 80 mL of iodixanol-320 (Visipaque, GE Healthcare, Chalfont St. Giles, United Kingdom) or iomeprol-400 (Iomeron, Bracco Imaging SpA, Milan, Italy) at 5 mL/s. Mean, minimum, maximum heart rate, and its variation (max-min) were assessed during calcium scoring scan and coronary DS-CTA. Three off-site readers independently evaluated the image sets in terms of technical adequacy, reasons for inadequacy, vessel visualization, diagnostic confidence (based on a 5-point scale), and arterial contrast opacification in Hounsfield units (HUs). Results: Ninety-six patients were included in the final evaluation. No significant differences were observed for pre-and postdose heart rate values for iomeron-400 compared with iodixanol-320, and changes in heart rate variation were also not significantly different (-2.3 ± 11.7 vs.-2.5 ± 7.3 bpm, P > 0.1). Contrast measurements in all analyzed vessels were significantly higher for iomeprol-400 (mean, 391.5-441.4 HU) compared with iodixanol-320 (mean, 332.3-365.5 HU, all P ≤ 0.0038). There was no significant difference in qualitative visualization of coronary arteries (mean scores, 4.3-4.5 for iomeprol, 4.1-4.3 for iodixanol, P = 0.15-0.28), or in diagnostic confidence scores. HU were inversely correlated with the number of insufficiently opacified segments (all readers P ≤ 0.0006). Conclusions: The high-iodine concentration contrast medium iomeprol-400 demonstrated significant benefit for coronary arterial enhancement compared with the iso-osmolar contrast medium iodixanol-320 when administered at identical flow rates and volumes for coronary DS-CTA. In addition, higher enhancement levels were found to be associated with lower numbers of inadequately visualized segments. Finally, observed mean heart rate changes after intravenous contrast injection were generally small during the examination and comparable for both agents.
AB - Objectives: To compare a contrast agent with high iodine concentration with an iso-osmolar contrast agent for coronary dual-source computed tomography angiography (DS-CTA), and to assess whether the contrast agent characteristics may affect the diagnostic quality of coronary DS-CTA. Materials and Methods: Patients were randomized to receive either 80 mL of iodixanol-320 (Visipaque, GE Healthcare, Chalfont St. Giles, United Kingdom) or iomeprol-400 (Iomeron, Bracco Imaging SpA, Milan, Italy) at 5 mL/s. Mean, minimum, maximum heart rate, and its variation (max-min) were assessed during calcium scoring scan and coronary DS-CTA. Three off-site readers independently evaluated the image sets in terms of technical adequacy, reasons for inadequacy, vessel visualization, diagnostic confidence (based on a 5-point scale), and arterial contrast opacification in Hounsfield units (HUs). Results: Ninety-six patients were included in the final evaluation. No significant differences were observed for pre-and postdose heart rate values for iomeron-400 compared with iodixanol-320, and changes in heart rate variation were also not significantly different (-2.3 ± 11.7 vs.-2.5 ± 7.3 bpm, P > 0.1). Contrast measurements in all analyzed vessels were significantly higher for iomeprol-400 (mean, 391.5-441.4 HU) compared with iodixanol-320 (mean, 332.3-365.5 HU, all P ≤ 0.0038). There was no significant difference in qualitative visualization of coronary arteries (mean scores, 4.3-4.5 for iomeprol, 4.1-4.3 for iodixanol, P = 0.15-0.28), or in diagnostic confidence scores. HU were inversely correlated with the number of insufficiently opacified segments (all readers P ≤ 0.0006). Conclusions: The high-iodine concentration contrast medium iomeprol-400 demonstrated significant benefit for coronary arterial enhancement compared with the iso-osmolar contrast medium iodixanol-320 when administered at identical flow rates and volumes for coronary DS-CTA. In addition, higher enhancement levels were found to be associated with lower numbers of inadequately visualized segments. Finally, observed mean heart rate changes after intravenous contrast injection were generally small during the examination and comparable for both agents.
KW - Coronary arteries
KW - Dual-source computed tomography
KW - Heart rate
KW - Hounsfield units (HU)
KW - Iodixanol
KW - Iomeprol
UR - http://www.scopus.com/inward/record.url?scp=79959931045&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959931045&partnerID=8YFLogxK
U2 - 10.1097/RLI.0b013e31821c7ff4
DO - 10.1097/RLI.0b013e31821c7ff4
M3 - Article
VL - 46
SP - 457
EP - 464
JO - Investigative Radiology
JF - Investigative Radiology
SN - 0020-9996
IS - 7
ER -